1 / 1

Partial agonist at nicotinic acetyl choline Receptors. 3

Asymmetric Synthesis of the Lupin Alkaloids: (-)-Cytisine, (-)-Sparteine, (+)-Anagyrine, and (+)- Thermopsine. Grounds for Synthesis. Alexander Bisset 1 , Martin Wills 1 , Teyrnon Jones 2 University of Warwick; 2) AstraZeneca R&D, Charnwood. PhD AIMS

kacy
Download Presentation

Partial agonist at nicotinic acetyl choline Receptors. 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Asymmetric Synthesis of the Lupin Alkaloids:(-)-Cytisine, (-)-Sparteine, (+)-Anagyrine, and (+)-Thermopsine Grounds for Synthesis Alexander Bisset1, Martin Wills1, Teyrnon Jones2 University of Warwick; 2) AstraZeneca R&D, Charnwood • PhD AIMS • To complete the asymmetric synthesis of: • (-)-cytisine, (-)-sparteine, (+)-anagyrine, • and (+)-thermopsine • To Synthesise desirable cytisine • derivatives for pharmaceutical research Partial agonist at nicotinic acetyl cholineReceptors.3 Therapeutic use in: smoking cessation and neurodegenerational diseases. (-)-cytisine Background - Asymmetric Alkene Hydrogenation Hydrogenation of N-acylaminoacrylates (1) is highly selective with catalysts such as [Rh(DuPHOS)COD]BF4 (2)1. Mechanistically, hydrogenation is likely to proceed through the co-ordination mode 32 This gave the precedent for the hydrogenation of 5 - a potential (-)-cytisine precursor, which could potentially be reduced in the same way (4). (-)-sparteine Used in catalysis as a chiral bidentateligand4 (+)-anagyrine (+)-thermopsine Some therapeutic uses. Used as precursors in the synthesis of (-)-sparteine analogues.4 Results - Hydrogenation This successful reduction was highly enantioselective with 94.5 % ee and 89 % conversion under optimised conditions. Some over reduction of the pyridone ring was observed (~11 % conv.) ee’swere determined by HPLC Although asymmetric syntheses of the alkaloids exist, none have proceeded via asymmetric hydrogenation. A preliminary study by Akira Shiibashi showed the hydrogenation of 5 successful with high ee. Future Work - Completion of the Synthesis From compound 7, completion of the synthesis is known.4 This compound could potentially be reached by the regioselective reduction of imide 6. References: 1. Burk, M. F.; Gross, J. P. J. Am. Chem. Soc., 1995 2. Heller, D.; Holz, J. J. Org. Chem. 2001, 66, 6816 3. Stead, D.; O’Brien, P.; Sanderson, A. J. Organic Letters,2005, 7, 4459 4. Gallagher, T.; Gray, D. Angew. Chem. Int. Ed., 2006,45, 2419

More Related